PRE-REGISTRATION (STEP 0)

Age >= 18 years

Pathologically proven diagnosis of squamous cell carcinoma (including variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma not otherwise specified [NOS]) of the head/neck (oral cavity, oropharynx, hypopharynx or larynx); pathologic stage III or IVA (American Joint Committee on Cancer [AJCC] 8): T3-T4a, N0-3, M0 or T1-T2, N1-3, M0

Patient has undergone total resection of the primary tumor with curative intent
* NOTE: Patient is to be pre-registered to screening (Step 0) and tissue submitted to Foundation Medicine as soon as possible after surgery in order to meet the 8 week deadline to register the patient to Step 1 after surgery; full assay minimum turn-around time is 17-24 days

For oropharynx primary tumors, the patient must have negative human papillomavirus (HPV) status of the tumor as determined by p16 protein expression using immunohistochemistry (IHC)

Patients with, per the operative and/or pathology report, positive margin(s) (tumor present at the cut or inked edge of the tumor) which is not superceded by an additional margin of tumor-negative tissue, nodal extracapsular extension, and/or gross residual disease after surgery are not eligible

A paraffin-embedded surgical tumor tissue specimen has been located is available for shipment to Foundation Medicine, Inc. following pre-registration
* NOTE: Complete the EA3132-specific FoundationOne requisition form

Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix and/or non-melanomatous skin cancer; patients must not have received chemotherapy or investigational therapy within two years of surgical resection of the primary tumor

Patient must not have had previous irradiation to the head and neck that would result in overlap in radiation fields for the current disease

Patients with recurrent disease or multiple primaries are ineligible

RANDOMIZATION (STEP 1)

NOTE: Patient must meet all eligibility criteria outlined in pre-registration; patient may not be randomized until site has been notified that the central determination of p53 mutation status of the surgical tumor tissue has been completed and site has been notified of assay completion

Per the operative report, the gross total resection of the primary tumor with curative intent was completed within 8 weeks prior to randomization

The patient must have the following assessments done =< 8 weeks prior to randomization:
* Examination by a head and neck surgeon
* Chest x-ray (or chest CT scan or CT/PET of the chest or MRI) to rule out distant metastatic disease

Patient has Eastern Cooperative Oncology Group (ECOG) performance status 0-1 within 2 weeks prior to randomization

Women must not be pregnant or breast-feeding due to exposure to cisplatin chemo-and/or radiotherapy; females of childbearing potential must have a blood or urine study within 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study and until 60 days from the last study treatment

Absolute neutrophil count >= 1,500/mm^3 (within 4 weeks prior to randomization)

Platelets >= 100,000/mm^3 (within 4 weeks prior to randomization)

Total bilirubin =< the upper limit of normal (ULN) (within 4 weeks prior to randomization)

Calculated creatinine clearance must be > 60 ml/min using the Cockcroft-Gault formula (within 4 weeks prior to randomization)

Patient must not have an intercurrent illness likely to interfere with protocol therapy

PRIMARY OBJECTIVE:
I. To evaluate the disease-free survival (DFS) of patients with stage III-IV squamous cell carcinoma of the head and neck (SCCHN) and disruptive p53 mutations after primary surgical resection followed by postoperative radiotherapy (PORT) alone or PORT with concurrent cisplatin.

SECONDARY OBJECTIVES:
I. To evaluate the DFS of patients with stage III-IV SCCHN and non-disruptive p53 mutations after primary surgical resection followed by PORT alone or PORT with concurrent cisplatin.
II. To evaluate the DFS of patients with stage III-IV SCCHN and p53 wild type after primary surgical resection followed by PORT alone or PORT with concurrent cisplatin.
III. To evaluate toxicities of PORT alone or PORT with concurrent cisplatin.
IV. To evaluate p53 mutation as a predictive biomarker of survival benefit given post-operative concurrent radiation and cisplatin.
V. To identify potential genomic alterations in addition to TP53 mutations that may be developed to a novel treatment approach.

PRIMARY FINANCIAL TOXICITY OBJECTIVE:
I. To assess delays in definitive diagnosis for Black patients with SCCHN enrolled in EA3132.

SECONDARY FINANCIAL TOXICITY OBJECTIVE:
I. To assess levels of financial toxicity of Black patients with SCCHN enrolled in EA3132.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM A: Patients undergo intensity-modulated radiation therapy (IMRT) once daily (QD) 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaire for up to 10-15 minutes 3 months after treatment. 

ARM B: Patients undergo IMRT QD 5 days a week and receive cisplatin intravenously (IV) over 1-2 hours weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. 

All patients undergo x-ray imaging, computed tomography (CT), positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI) during screening and follow up. Patients also undergo blood sample collection throughout the trial. 

After completion of study treatment, patients are followed up every 6 months for 3 years and then every 12 months for 7 years.